Physicians' Academy for Cardiovascular Education

Lipids

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.

Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.

Measured Lp(a) levels and LPA GRS similarly associated with ASCVD risk in primary prevention setting

News - Oct. 7, 2020

EAS 2020 In participants of the UK Biobank, a LPA genetic risk score and measured Lp(a) levels provided comparable risk prediction for ASCVD risk in a primary prevention setting.

ANGPTL3 inhibition reduces LDL-c in HoFH patients with limited to no LDL receptor activity

News - Oct. 6, 2020

EAS 2020 Inhibition of ANGPTL3 with evinacumab reduced LDL-c levels significantly in HoFH patients with little to no LDL receptor function.

LDL-c lowering by RNAi against PCKS9 similar across HeFH genotype subgroups

News - Oct. 6, 2020

EAS 2020 A subanalysis of ORION-9 showed that lowering of LDL-c by inclisiran was similar across subgroups of genotypes in those with heterozygous FH.

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD
Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Icosapent ethyl reduces low attenuation plaque quantity

News - Aug. 29, 2020
**ESC 2020** The EVAPORATE trial showed that icosapent ethyl 4g/day, compared with placebo, significantly reduced multiple plaque components in patients with elevated triglycerides on statin therapy

ESC 2020 The EVAPORATE trial showed that icosapent ethyl 4g/day, compared with placebo, significantly reduced multiple plaque components in patients with elevated triglycerides on statin therapy

PCSK9i initiated within 24 hours of ACS presentation rapidly lowers LDL-c

Literature - Aug. 24, 2020 - Leucker TM et al., - Circulation. 2020 Jul 28;142(4):419-421.

This trial in 57 patients with non-STEMI and troponin I ≥5 ng/mL showed that more patients reach LDL-c targets at hospital discharge with evolocumab plus high-intensity statin therapy compared with placebo plus high-intensity statin therapy.

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD
 Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Elevated Lp(a) levels associated with increased risk of MACE when hsCRP ≥2 mg/L

Literature - July 27, 2020 - Puri R et al., - JAMA Cardiol. 2020.

Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.

Higher frequency of coronary atherosclerotic plaques in patients with genetically confirmed FH

Literature - July 7, 2020 - Pang J et al., - Atherosclerosis. 2020.

Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD
In this video internist Kees Hovingh discusses why screening for FH is important and tools used for its diagnosis.

In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.